Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting
Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…Abstract Number: 1312 • 2014 ACR/ARHP Annual Meeting
Features, Treatment and Outcome of Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening inflammatory complication of pediatric systemic lupus erythematosus (pSLE). There are few reports of the presentation, treatment and outcome of…Abstract Number: 1311 • 2014 ACR/ARHP Annual Meeting
Lupus Nephritis in Mexican Children
Background/PurposeIncidence and disease pattern of childhood-onset systemic lupus erythematosus (SLE) is reported to differ among ethnic groups. Lupus nephritis (LN) strongly affects the outcome in…Abstract Number: 1310 • 2014 ACR/ARHP Annual Meeting
Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis
Background/Purpose It can be difficult to differentiate macrophage activation syndrome (MAS) from active pediatric systemic lupus erythematosus (pSLE). However, this differentiation is in determining correct…Abstract Number: 1309 • 2014 ACR/ARHP Annual Meeting
Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood – Onset Systemic Lupus Erythematosus?
Background/Purpose: Biomarkers proven to be effective in aSLE patients may not directly apply to cSLE unless validation is done. Existing evidences have shown immunopathogenic roles…Abstract Number: 1308 • 2014 ACR/ARHP Annual Meeting
Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus
Background/Purpose: The role of antinucleosome antibodies (ANuA) in the immunopathogenesis of SLE is evident. ANuA was shown to be a good, if not better than…Abstract Number: 1307 • 2014 ACR/ARHP Annual Meeting
Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients
Background/Purpose: Mycophenolate mofetil (MMF) is often used to treat lupus nephritis (LN) and extra-renal lupus in children with SLE. Plasma levels of mycophenolic acid (MPA)…Abstract Number: 1306 • 2014 ACR/ARHP Annual Meeting
Outcome of Lupus Nephritis in Children Less Than 12 Years Old from North-India
Background/Purpose Studies on lupus nephritis in young children below 12 years of age from developing countries are limited. This study looks at long-term outcome in…Abstract Number: 1305 • 2014 ACR/ARHP Annual Meeting
Adiposity and Adipokines Are Associated with Insulin Resistance in Pediatric Systemic Lupus Erythematosus
Background/Purpose: Traditional risk factors for cardiovascular disease do not fully account for the increase in atherosclerosis in SLE. Insulin resistance (IR) and other metabolic derangements…Abstract Number: 1304 • 2014 ACR/ARHP Annual Meeting
Development of an Index to Non-Invasively Quantify Lupus Nephritis Chronicity in Children
Background/Purpose: The current gold standard for assessing chronic changes in Lupus Nephritis (LN) is a kidney biopsy interpreted using the International Societies for Nephrology &…Abstract Number: 1303 • 2014 ACR/ARHP Annual Meeting
Accuracy of Laboratory Measures and Clinical Renal Activity Indices for Reflecting Biopsy-Proven Lupus Nephritis (LN) Activity
Background/Purpose : LN is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Kidney biopsies are impractical to assess the course of LN given their invasiveness and…Abstract Number: 1321 • 2014 ACR/ARHP Annual Meeting
A Pilot Study to Evaluate the Feasibility of Conducting Juvenile Localized Scleroderma Comparative Effectiveness Treatment Studies
Background/Purpose Juvenile localized scleroderma (jLS) often causes severe morbidity in the developing child, including growth defects and disfigurement. Optimal therapy is not known. The…Abstract Number: 1320 • 2014 ACR/ARHP Annual Meeting
Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher thrombotic risk compared to the general population, and arterial and venous thromboses impart substantial morbidity…Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…Abstract Number: 1318 • 2014 ACR/ARHP Annual Meeting
Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups
Background/Purpose: To evaluate features of JIIM clinical and Ab subgroups at illness onset. Methods: Physician-completed questionnaires illness onset features were reviewed in 465 JIIM pts…